Our goal is to deliver A.I. based patient specific, clinical decision support applications to improve quality, outcomes and reduce healthcare costs. To accomplish this, we consider all the multidimensional patient data; raw imaging concurrently with other relevant patient data at the leading edge of machine learning technologies. We want every physician to be a life-saving expert, every time. This is what drives us forward every day.

MedyMatch is a company founded in Deep Learning and Machine Vision (‘Deep Vision’). Our team of artificial intelligence, deep learning and machine vision experts with our world class clinical partners are innovating at the confluence of deep clinical knowhow, machine vision and learning to yield unprecedented insight into unstructured medical data.

MedyMatch has developed a generalized deep vision platform capable of considering the full richness of medical imaging along with any other patient data. This platform and A.I. approach will facilitate rapid discovery and decision support development.

Despite the introduction of more modern diagnostic techniques and of intensive and invasive monitoring, the number of missed major diagnoses has not essentially changed over the past 20 to 30 years”. Studies have shown between 30% of all medical imaging diagnoses are incorrect and 80% of those errors are perceptual errors that are present but go unnoticed by the human eye.

The Cost of Stroke: Stroke is currently the 4th leading cause of death, the #2 killer in the world and the #1 cause of adult disability. Per the American Heart/Stroke Association forecast for 2030, there will be 3.4 million stroke victims predicted, generating $240 billion in total direct and indirect costs

Our intent is to continue to reapply our A.I. platform capability to new and diverse clinical problems with interest in continuing to build out capability in the acute care ER setting with a natural extension into trauma.

Structured problem solving and collaboration are key to realizing the full potential of Deep Vision. With the right partners and data, there is a strong desire and potential to address more chronic diseases such as neurodegenerative disease, Cerebrovascular disease and PTSD. The pipeline of potential treatments will require definitive complementary diagnosis and prognosis. This is an ideal challenge for deep machine vision and learning.